Nkarta (NKTX) Net Cash Flow (2019 - 2026)
Nkarta (NKTX) posted quarterly Net Cash Flow of -$12.3 million for Q1 2026, down 149.66% year-over-year from $24.7 million in Q1 2025, and up 40.05% quarter-over-quarter from -$20.5 million in Q4 2025.
Nkarta (NKTX) Net Cash Flow (2019 - 2026) Analysis & Trends
Nkarta's Net Cash Flow history runs 8 years deep, the most recent figure standing at -$12.3 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 149.66% year-over-year to -$12.3 million; the TTM figure through Mar 2026 stood at -$25.2 million (up 87.23% YoY), while the FY2025 annual figure was $11.8 million, up 471.36% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$12.3 million, up from -$20.5 million in the prior quarter.
- The five-year high for Net Cash Flow was $219.2 million in Q1 2024, with the low at -$129.9 million in Q2 2024.
- The 5-year median for Net Cash Flow is -$7.2 million (2023), against an average of -$1.9 million.
- Peak annual rise in Net Cash Flow reached 1255.71% in 2024, while the deepest fall reached 793.69% in 2024.
- Nkarta's Net Cash Flow stood at -$2.2 million in 2022, then tumbled by 234.35% to -$7.2 million in 2023, then plunged by 302.76% to -$29.1 million in 2024, then rose by 29.59% to -$20.5 million in 2025, then jumped by 40.05% to -$12.3 million in 2026.
- Business Quant data shows NKTX's Net Cash Flow at -$12.3 million in Q1 2026, -$20.5 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | -2.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.40 Mn |
| Jun 30, 2026 | -2.40 Mn |
| Mar 31, 2026 | -12.28 Mn |
| Mar 31, 2026 | -12.28 Mn |
| Dec 31, 2025 | -20.48 Mn |
| Dec 31, 2025 | -20.48 Mn |
| Sep 30, 2025 | 6.70 Mn |
| Sep 30, 2025 | 6.70 Mn |
| Jun 30, 2025 | 816,000.00 |
| Jun 30, 2025 | 816,000.00 |
| Mar 31, 2025 | 24.73 Mn |
| Mar 31, 2025 | 24.73 Mn |
| Dec 31, 2024 | -29.09 Mn |
| Dec 31, 2024 | -29.09 Mn |
| Sep 30, 2024 | -63.44 Mn |
| Sep 30, 2024 | -63.44 Mn |
| Jun 30, 2024 | -129.89 Mn |
| Jun 30, 2024 | -129.89 Mn |
| Mar 31, 2024 | 219.25 Mn |
| Mar 31, 2024 | 219.25 Mn |